Your browser is no longer supported. Please, upgrade your browser.
NKTX Nkarta, Inc. daily Stock Chart
Nkarta, Inc.
Index- P/E- EPS (ttm)- Insider Own9.70% Shs Outstand29.50M Perf Week-9.46%
Market Cap903.00M Forward P/E- EPS next Y-1.98 Insider Trans363.06% Shs Float27.81M Perf Month27.12%
Income- PEG- EPS next Q-0.42 Inst Own- Short Float3.76% Perf Quarter-
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio3.98 Perf Half Y-
Book/sh- P/B- EPS next Y60.60% ROA- Target Price43.33 Perf Year-
Cash/sh0.73 P/C41.81 EPS next 5Y- ROE- 52W Range22.46 - 58.69 Perf YTD-36.10%
Dividend- P/FCF- EPS past 5Y- ROI90.60% 52W High-47.84% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low36.29% ATR3.04
Employees70 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)51.95 Volatility10.59% 11.49%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.67 Prev Close31.29
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume262.81K Price30.61
Recom1.70 SMA202.75% SMA507.20% SMA2004.18% Volume176,726 Change-2.17%
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Aug-04-20Initiated Evercore ISI Outperform $55
Aug-04-20Initiated Cowen Outperform
Sep-08-20 04:02PM  
Aug-20-20 04:02PM  
Jul-31-20 04:42PM  
Jul-14-20 04:39PM  
Jul-10-20 11:30AM  
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EPossible Member of 10% GroupJul 14Buy18.001,000,00018,000,0001,209,936Jul 14 11:39 AM
Florence Anthony A. Jr.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
BASKETT FOREST10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
MAKOWER JOSHUA10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Makhzoumi Mohamad10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Sonsini Peter W.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
SANDELL SCOTT D10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
New Enterprise Associates 15, 10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Novo Holdings A/S10% OwnerJul 14Buy18.00555,5559,999,9902,793,865Jul 16 04:41 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJul 14Buy18.003,333,33359,999,9945,605,129Jul 16 04:30 PM
GLAXOSMITHKLINE PLCDirectorJul 14Buy18.00833,33314,999,9943,150,732Jul 16 08:13 PM